Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
necitumumab + osimertinib + trastuzumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
A combination of three targeted cancer therapies:\n\n- **Necitumumab**: A recombinant human IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and blocks ligand binding, preventing receptor activation and downstream signaling.\n\n- **Osimertinib**: A small molecule EGFR tyrosine kinase inhibitor that specifically targets both EGFR sensitizing mutations and EGFR T790M resistance mutations.\n\n- **Trastuzumab**: A monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) protein.
- Brand names
- TagrissoPortrazzaHerceptinHerzumaOgivriOntruzantKanjintiHercessiTrazimera
- Other names
- osimertinib + necitumumab + trastuzumab
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on necitumumab + osimertinib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on necitumumab + osimertinib + trastuzumab.